U.S. FDA cuts gap for Moderna COVID-19 booster dose as cases surge

·1-min read

(Reuters) -The U.S. Food and Drug Administration on Friday shortened the interval between the primary series of Moderna Inc's COVID-19 vaccine and a booster dose to five months, as it looks to bolster protection against the fast-spreading Omicron variant. 

  The agency expects the shorter interval, reduced by a month for people aged 18 and above, will provide better protection sooner against the variant, which is driving up infections and overwhelming hospitals. 

  The United States reported 662,000 new COVID-19 cases on Thursday, the fourth highest daily U.S. total ever recorded. The Omicron-driven surge in U.S. COVID-19 cases has likely not topped out yet, the Centers for Disease Control and Prevention said on Friday. 

  The FDA earlier this week cut the interval to get a booster dose of Pfizer and BioNTech COVID-19 vaccine, based on mRNA technology like Moderna's, to five months from six. 

  "Vaccination is our best defense against COVID-19, including the circulating variants, and shortening the length of time between completion of primary series and a booster dose may help reduce waning immunity," Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said. 

  People who received Johnson & Johnson's single-dose COVID-19 vaccine can get a booster dose two months later. 

Video: What we know about the omicron variant

  (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli) 

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting